Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

5.5K
5.5K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

229
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
229
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

543
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
543
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

16
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spontaneous Acute Left-Sided Abdominal Pain in a Patient With AL Amyloidosis.

EJHaem·2026
Same author

Outcomes of acute myeloid leukemia patients admitted to the intensive care unit within 100 days of allogeneic hematopoietic stem cell transplantation.

The American journal of the medical sciences·2026
Same author

Fully human BCMA CAR-T therapy in multiple myeloma: lessons from long-term follow-up.

Translational cancer research·2026
Same author

Neighborhood Socioeconomic Disadvantage and Distance From Treatment Center do not Impact Survival Outcomes of Patients With Non-Hodgkin Lymphoma and Multiple Myeloma Treated With CAR T-Cell Therapies.

Transplantation and cellular therapy·2026
Same author

Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention.

Cancer research communications·2026
Same author

In Reply: Diagnostic challenges in severe autoimmune hemolysis.

Cleveland Clinic journal of medicine·2026

Related Experiment Video

Updated: Jul 30, 2025

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
10:04

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

13.5K

Systemic AL amyloidosis: current approach and future direction.

Maroun Bou Zerdan1, Lewis Nasr2, Farhan Khalid3

  • 1Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA.

Oncotarget
|May 15, 2023
PubMed
Summary

Systemic Light chain amyloidosis (AL) is a fatal plasma cell disorder causing organ damage. Early diagnosis and treatment are crucial, with ongoing research into novel therapies and maintenance strategies.

Keywords:
amyloidosismanagement

More Related Videos

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

7.8K
Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
13:31

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Published on: February 12, 2015

8.8K

Related Experiment Videos

Last Updated: Jul 30, 2025

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
10:04

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

13.5K
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

7.8K
Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
13:31

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Published on: February 12, 2015

8.8K

Area of Science:

  • Hematology
  • Oncology
  • Nephrology

Background:

  • Systemic Light chain (AL) amyloidosis is a plasma cell disorder with amyloidogenic light chain fragment deposition.
  • It frequently affects renal and cardiovascular systems, leading to organ dysfunction and potentially death.
  • Early diagnosis and staging are critical for effective treatment planning.

Purpose of the Study:

  • To review the latest treatment updates for AL amyloidosis.
  • To highlight ongoing clinical trials and future therapeutic directions.
  • To discuss challenges in treatment, including patient eligibility for hematopoietic cell transplantation (HCT).

Main Methods:

  • Literature review of systemic AL amyloidosis treatments.
  • Analysis of diagnostic methods including tissue biopsy, Congo red staining, and mass spectrometry.
  • Evaluation of staging and biomarker testing for organ involvement.
  • Review of treatment options, including autologous HCT and induction/maintenance therapies.

Main Results:

  • Autologous HCT post-bortezomib induction is effective but not feasible for many patients due to age, frailty, or organ failure.
  • Complete hematologic response is the goal, but post-HCT maintenance therapy is not well-established.
  • Numerous novel treatments and clinical trials are underway to improve outcomes.

Conclusions:

  • AL amyloidosis requires timely diagnosis and tailored treatment strategies.
  • Patient selection for HCT remains a significant challenge.
  • Further research into novel therapies and maintenance strategies is essential for improving survival and quality of life in AL amyloidosis patients.